OSOlga V. Shcherbakova

Olga V. Shcherbakova

*This is an algorithmically generated author record based on publicly available information.

Olga V. Shcherbakova has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Humoral and Cellular Immune Response to the Genetically Detoxified S1 Subunit of Pertussis Toxin in Mice

    by V. A. Shokina, A. V. Maleeva, V. P. Volok, O. V. Shcherbakova, N. E. Postika, A. V. Melikhova, D. Y. Mokhirev, A. A. Tikhonova, D. Engin, A. V. Lukina-Gronskaya, et al.

    Bordetella pertussis, a gram-negative bacterium responsible for whooping cough, poses severe health risks, especially to young children. However, the disease can be prevented by immunization with whole-cell pertussis vaccines and acellular pertussis vaccines containing 2–5 purified B. pertussis antigens, of which chemically detoxified pertussis toxin is the main protective component. While current vaccines have proven effective, concerns over high reactogenicity of whole-cell pertussis vaccines and the waning immunity to acellular pertussis vaccines formulations underscore the need for improved pertussis vaccines. Genetically detoxified pertussis toxin is an attractive vaccine candidate because it retains most of the structural properties of native pertussis toxin and better preserves the protective epitopes compared to detoxified pertussis toxin. In this study, we developed a candidate vaccine based on a genetically detoxified pertussis toxin S1 subunit, gd15PTxS1. We evaluated humoral and cellular immunogenicity of gd15PTxS1 in a murine model and demonstrated significant anti-PTx IgG seroconversion and a balanced Th1/Th2/Th17 T-cell response, with gd15PTxS1 inducing robust cytotoxic and helper T-cell activation comparable to that of the whole-cell pertussis vaccines. Our results show that gd15PTxS1 is highly immunogenic in mice and is a promising vaccine candidate for further protectivity studies.

  • Open Access

    Clonal diversity determines persistence of SARS-CoV-2 epitope-specific T cell response

    by Ksenia V. Zornikova, Alexandra Khmelevskaya, Savely A. Sheetikov, Dmitry O. Kiryukhin, Olga V. Shcherbakova, Aleksei Titov, Ivan V. Zvyagin, Grigory A. Efimov

    T cells play a pivotal role in reducing disease severity during SARS-CoV-2 infection and formation of long-term immune memory. We studied 50 COVID-19 convalescent patients and found that T cell response was induced more frequently and persisted longer than circulating antibodies. To identify epitopes that give rise to long-lived T cell memory, we performed ex vivo T cell expansion, MHC-tetramer cell-sorting, and high-throughput sequencing. We identified 756 clonotypes specific to nine known CD8 + T cell receptor (TCR) epitopes. Some epitopes were recognized by highly similar public clonotypes with restricted variable and joining segment usage. Receptors for other epitopes were extremely diverse, suggesting alternative modes of recognition. We also tracked persistence of epitope-specific response and individual clonotypes for a median of eight months after infection. The number of recognized epitopes per patient and quantity of epitope-specific clonotypes decreased over time, but the studied epitopes were characterized by uneven decline in the number of specific T cells. Epitopes with more clonally diverse TCR repertoires induced more pronounced and durable responses. In contrast, the abundance of specific clonotypes in peripheral circulation had no influence on their persistence. Our study demonstrates the durability of SARS-CoV-2-specific CD8 + memory, and offers important implications for vaccine design.

  • Open Access

    Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2

    by Aleksei Titov, Regina Shaykhutdinova, Olga V. Shcherbakova, Yana Serdyuk, Savely A. Sheetikov, Ksenia V. Zornikova, Alexandra V. Maleeva, Alexandra Khmelevskaya, Dmitry V. Dianov, Naina T. Shakirova, et al.

    The ongoing COVID-19 pandemic calls for more effective diagnostic tools, and T cell response assessment can serve as an independent indicator of prior COVID-19 exposure while also contributing to a more comprehensive characterization of SARS-CoV-2 immunity. In this study, we systematically assessed the immunogenicity of 118 epitopes with immune cells collected from multiple cohorts of vaccinated, convalescent, and healthy unexposed and SARS-CoV-2 exposed donors. We identified seventy-five immunogenic epitopes, 24 of which were immunodominant. We further confirmed HLA restriction for 49 epitopes, and described association with more than one HLA allele for 14 of these. After excluding two cross-reactive epitopes that generated a response in pre-pandemic samples, we were left with a 73-epitope set that offers excellent diagnostic specificity without losing sensitivity compared to full-length antigens, which evoked a robust cross-reactive response. We subsequently incorporated this set of epitopes into an in vitro diagnostic ‘Corona-T-test’ which achieved a diagnostic accuracy of 95% in a clinical trial. When applied to a cohort of asymptomatic seronegative individuals with a history of prolonged SARS-CoV-2 exposure, this test revealed a lack of specific T cell response combined with strong cross-reactivity to full-length antigens, indicating that abortive infection had occurred in these individuals.